These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10918519)

  • 1. Preclinical assessments of european union marketing authorisation applications for immunomodulatory biopharmaceuticals.
    Liminga U
    Hum Exp Toxicol; 2000 Apr; 19(4):257-60. PubMed ID: 10918519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety evaluation of immunomodulatory biopharmaceuticals: can we improve the predictive value of preclinical studies?
    Black LE; Green JD; Rener J; Dayan A; Cavagnaro JA; Spindler P; Bussiere JL; Bouchard P; Inoue T; Thomas PT; Essayan DM; Gillett NA; Hart TK; Hastings K; House RV; Latta D; Liminga U; Treacy G; Wierda D
    Hum Exp Toxicol; 2000 Apr; 19(4):205-7. PubMed ID: 10918508
    [No Abstract]   [Full Text] [Related]  

  • 3. Overview status of preclinical safety assessment for immunomodulatory biopharmaceuticals.
    Green JD; Black LE
    Hum Exp Toxicol; 2000 Apr; 19(4):208-12. PubMed ID: 10918509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Procedure for the marketing authorization of an antibacterial agent].
    López Navas A; García-Escribano Ráez N; Flores Juberías Á; Suárez Gea ML
    Enferm Infecc Microbiol Clin; 2014 Oct; 32(8):529-32. PubMed ID: 25124488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Overregulation and unnecessary animal testing: requirements for market approval of biopharmaceuticals too rigid].
    Schellekens H
    Ned Tijdschr Geneeskd; 2012; 156(50):A5723. PubMed ID: 23231875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biopharmaceuticals approved in the EU 1995-1999: a European Union-United States comparison.
    Reichert JM; Healy EM
    Eur J Pharm Biopharm; 2001 Jan; 51(1):1-7. PubMed ID: 11154897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European regulatory use and impact of subgroup evaluation in marketing authorisation applications.
    Tanniou J; Teerenstra S; Hassan S; Elferink A; van der Tweel I; Gispen-de Wied C; Roes KCB
    Drug Discov Today; 2017 Dec; 22(12):1760-1764. PubMed ID: 28943304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical review on the Environmental Risk Assessment of medicinal products for human use in the centralised procedure.
    Caneva L; Bonelli M; Papaluca-Amati M; Vidal JM
    Regul Toxicol Pharmacol; 2014 Apr; 68(3):312-6. PubMed ID: 24447908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The review of drug applications submitted to the European Medicines Evaluation Agency: frequently raised objections, and outcome.
    Pignatti F; Aronsson B; Gate N; Vamvakas S; Wade G; Moulon I; Le Courtois P
    Eur J Clin Pharmacol; 2002 Dec; 58(9):573-80. PubMed ID: 12525957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory considerations on new adjuvants and delivery systems.
    Sesardic D
    Vaccine; 2006 Apr; 24 Suppl 2():S2-86-7. PubMed ID: 16823940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency].
    Enzmann H; Broich K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(2):120-8. PubMed ID: 23663906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thirty years of preclinical safety evaluation of biopharmaceuticals: Did scientific progress lead to appropriate regulatory guidance?
    Kooijman M; van Meer PJ; Moors EH; Schellekens H
    Expert Opin Drug Saf; 2012 Sep; 11(5):797-801. PubMed ID: 22861668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of global regulatory toxicology requirements for vaccines and adjuvants.
    Sun Y; Gruber M; Matsumoto M
    J Pharmacol Toxicol Methods; 2012 Mar; 65(2):49-57. PubMed ID: 22326278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [European Agency for the Evaluation of Medicinal Products: five years experience].
    Sauer F
    Bull Mem Acad R Med Belg; 2000; 155(5-6):254-8; discussion 259-62. PubMed ID: 11304960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of Clinical Trials with Advanced Therapy Medicinal Products in Germany.
    Renner M; Anliker B; Sanzenbacher R; Schuele S
    Adv Exp Med Biol; 2015; 871():87-101. PubMed ID: 26374214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
    Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
    Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of biopharmaceuticals. The European perspective.
    Schellekens H; Casadevall N
    Dev Biol (Basel); 2003; 112():23-8. PubMed ID: 12762501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. European union regulatory developments for new vaccine adjuvants and delivery systems.
    Sesardic D; Dobbelaer R
    Vaccine; 2004 Jun; 22(19):2452-6. PubMed ID: 15193409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Considerations in assessing the developmental and reproductive toxicity potential of biopharmaceuticals.
    Martin PL; Breslin W; Rocca M; Wright D; Cavagnaro J
    Birth Defects Res B Dev Reprod Toxicol; 2009 Jun; 86(3):176-203. PubMed ID: 19462404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune modulator studies in primates: the utility of flow cytometry and immunohistochemistry in the identification and characterization of immunotoxicity.
    Lappin PB; Black LE
    Toxicol Pathol; 2003; 31 Suppl():111-8. PubMed ID: 12597438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.